EHCHealthcare · Medical Care FacilitiesThe 13 Wall Street analysts covering Encompass Health Corp. hold a median 12-month price target of $150 — +23.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Encompass Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (90): The business earns solid, repeatable profits on what it owns.
Accruals (53): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on EHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.2% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | TD Cowen | Maintains | Buy | $125 → $140 |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | $140 → $150 |
| 7 Aug 2026 | UBS | Maintains | Buy | $150 → $155 |
| 6 Aug 2026 | Barclays | Maintains | Overweight | $140 → $144 |
| 28 May 2026 | TD Cowen | Initiates | Buy | $125 |
| 28 May 2026 | TD Cowen | Initiates | Buy | — |
| 5 May 2026 | Barclays | Maintains | Overweight | — |
| 6 Feb 2026 | Barclays | Maintains | Overweight | — |
| 30 Oct 2025 | Barclays | Maintains | Overweight | — |
| 2 Oct 2025 | UBS | Maintains | Buy | — |
| 16 Sept 2025 | Keybanc | Maintains | Overweight | — |
| 10 Sept 2025 | B of A Securities | Maintains | Buy | — |
| 14 Aug 2025 | Truist Securities | Maintains | Buy | — |
| 6 Aug 2025 | UBS | Maintains | Buy | — |
| 5 June 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 27 May 2025 | Keybanc | Maintains | Overweight | — |
| 28 Apr 2025 | RBC Capital | Maintains | Outperform | — |
| 28 Apr 2025 | Truist Securities | Reiterates | Buy | — |
| 28 Apr 2025 | UBS | Maintains | Buy | — |
| 25 Apr 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EHC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Encompass Health Corp. returned −2.2% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 37% of US stocks
Cheaper than 53% of US stocks
Cheaper than 22% of US stocks
Cheaper than 36% of US stocks
Higher than 51% of US stocks
Higher than 46% of US stocks
Higher than 98% of US stocks
Higher than 76% of US stocks
Higher than 70% of US stocks
Higher than 85% of US stocks
Higher than 92% of US stocks
Higher than 12% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Encompass Health Corp. has a market value of $12.0B and an enterprise value of $15.6B.
Revenue in the twelve months to 30 June 2026: $6.2B. The latest quarter grew 9.6% year on year.
Net income over the same four quarters: $833.3M, a 13.4% net margin.
Diluted earnings per share, trailing twelve months: $6.14.
Free cash flow in the twelve months to 30 June 2026: $413.4M.
Encompass Health Corp. spent $247.0M on share buybacks and $75.2M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 20.3×; forward P/E: 18.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.62%, paying out 13% of earnings.
Encompass Health Corp. employs 29,699 people — $209K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Encompass Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights Encompass Health (EHC) as a strong growth stock, pointing to its Zacks Style Scores as a way for investors to identify top-rated stocks based on investing style.
Why it matters — The article signals that EHC is being favorably ranked by an established research service, giving watchers a positive growth-oriented assessment of the company.
Zacks Investment Research highlights Encompass Health (EHC) as a strong value stock, using its Style Scores system to help investors find top-rated stocks based on investing style. The piece points to EHC's value characteristics as a reason for investor attention.
Why it matters — The item signals that EHC is being recognized for value-stock characteristics by a major research firm, which EHC watchers may view as a favorable assessment.
Encompass Health Rehabilitation Hospital of Lower Providence has opened in Eagleville, Pennsylvania. The new facility expands the company's presence in the state.
Why it matters — This opening indicates growth in Encompass Health's inpatient rehabilitation network, expanding its service footprint to a new Pennsylvania location.
Encompass Health reported earnings 30 days ago, and its stock has declined 1.8% since that report. The article examines what may lie ahead for the company following the earnings release.
Why it matters — EHC watchers would care because the piece focuses on the company's post-earnings stock performance and what factors could shape its outlook going forward.
Seeking Alpha published a bullish analysis of Encompass Health, describing it as the largest U.S. inpatient rehabilitation hospital operator with robust top- and bottom-line growth and industry-leading balance sheet strength. The article highlights EHC's disciplined expansion strategy targeting 6–10 new hospitals and 80–120 bed additions annually, supported by favorable US demographic trends, and notes its valuation remains attractive despite trading at a premium to peers.
Why it matters — A watcher would care because the piece affirms EHC's financial strength and growth trajectory, framing its premium valuation as justified by strong fundamentals and declining net leverage.
The 13 Wall Street analysts covering Encompass Health Corp. have a median 12-month price target of $150, with estimates ranging from $140 to $155. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Encompass Health Corp., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Encompass Health Corp. 80 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Encompass Health Corp. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +23.2% from the last close, and Ticker Nerd's factor model ranks Encompass Health Corp. 80 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Encompass Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $140 to $155 over the next 12 months.
Encompass Health Corp. returned -2.2% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Encompass Health Corporation is a post-acute healthcare company focused on inpatient rehabilitation hospitals. The company provides specialized, facility-based care for patients recovering from strokes, neurological disorders, brain and spinal cord injuries, cardiac and pulmonary conditions, complex orthopedic cases, amputations, and other serious illnesses or injuries.
The most recent item we track (Zacks Investment Research, 18 Sept 2026): "Here's Why Encompass Health (EHC) is a Strong Growth Stock". Zacks Investment Research highlights Encompass Health (EHC) as a strong growth stock, pointing to its Zacks Style Scores as a way for investors to identify top-rated stocks based on investing style.
Encompass Health Corporation is a post-acute healthcare company focused on inpatient rehabilitation hospitals. The company provides specialized, facility-based care for patients recovering from strokes, neurological disorders, brain and spinal cord injuries, cardiac and pulmonary conditions, complex orthopedic cases, amputations, and other serious illnesses or injuries. Its services combine medical, nursing, therapy, and ancillary support to help patients regain functional ability, independence, and quality of life. Encompass Health operates a national network of rehabilitation hospitals across the United States and Puerto Rico, making it a significant provider in the inpatient rehabilitation market. Based in Birmingham, Alabama, Encompass Health plays a central role in delivering coordinated recovery care for patients who need intensive, medically supervised rehabilitation after hospitalization.
CEO Mr. Mark J. Tarr · 29,699 employees · United States · https://www.encompasshealth.com
